Morgan Stanley initiated coverage of Vicarious Surgical with an Equal Weight rating and 60c price target. The firm sees positives for Vicarious, which is developing a single-port surgical robotic system, but it sees limited near-term catalysts to inflect value ahead of what it estimates to be a 2027 commercial launch, the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on RBOT:
- Vicarious Surgical price target lowered to $1.50 from $4 at Piper Sandler
- Vicarious Surgical downgraded to Neutral from Buy at BTIG
- Vicarious Surgical downgraded to Hold from Buy at Canaccord
- Vicarious Surgical sees FY23 cash burn $60M-$65M
- Vicarious Surgical reports Q3 adjusted EPS (12c), consensus (15c)
